- Home
- REGN vs WMB Comparison
REGN vs WMB Comparison
Compare REGN & WMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- WMB
- Stock Information
- Founded
- REGN 1988
- WMB 1908
- Country
- REGN United States
- WMB United States
- Employees
- REGN N/A
- WMB N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- WMB Natural Gas Distribution
- Sector
- REGN Health Care
- WMB Utilities
- Exchange
- REGN Nasdaq
- WMB Nasdaq
- Market Cap
- REGN 63.4B
- WMB 72.8B
- IPO Year
- REGN 1991
- WMB N/A
- Fundamental
- Price
- REGN $563.16
- WMB $58.62
- Analyst Decision
- REGN Buy
- WMB Buy
- Analyst Count
- REGN 23
- WMB 19
- Target Price
- REGN $971.57
- WMB $54.71
- AVG Volume (30 Days)
- REGN 1.1M
- WMB 8.9M
- Earning Date
- REGN 04-29-2025
- WMB 05-05-2025
- Dividend Yield
- REGN 0.16%
- WMB 3.41%
- EPS Growth
- REGN 10.27
- WMB N/A
- EPS
- REGN 38.34
- WMB 1.82
- Revenue
- REGN $14,202,000,000.00
- WMB $10,753,000,000.00
- Revenue This Year
- REGN $4.06
- WMB $10.92
- Revenue Next Year
- REGN $6.54
- WMB $10.16
- P/E Ratio
- REGN $14.69
- WMB $32.21
- Revenue Growth
- REGN 8.27
- WMB 8.06
- 52 Week Low
- REGN $525.99
- WMB $37.27
- 52 Week High
- REGN $1,211.20
- WMB $61.67
- Technical
- Relative Strength Index (RSI)
- REGN 37.15
- WMB 53.71
- Support Level
- REGN $544.50
- WMB $51.89
- Resistance Level
- REGN $575.20
- WMB $57.43
- Average True Range (ATR)
- REGN 28.44
- WMB 2.62
- MACD
- REGN -1.59
- WMB 0.04
- Stochastic Oscillator
- REGN 32.25
- WMB 69.91
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About WMB Williams Companies Inc. (The)
Williams Companies is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.